ELUTIA INC.
ELUT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ELUT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ELUT
Elutia Inc. is a commercial-stage medical technology company focused on drug-eluting biomatrix solutions for breast reconstruction, having divested its Orthobiologics and CIED businesses to concentrate on its EluPro product line.
Key risk: Profitability uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for ELUTIA INC..
Elutia Inc. is a commercial-stage medical technology company focused on drug-eluting biomatrix solutions for breast reconstruction, having divested its Orthobiologics and CIED businesses to concentrate on its EluPro product line.
- Elutia is transitioning to a pure-play drug-eluting biomatrix company, having sold its Orthobiologics and CIED businesses [sec_mda · as of 2026-03-13].
- As of June 30, 2026, Elutia reported cash & equivalents of $19.9M, total revenue of $2.4M, and a net loss of -$7.6M [sec].
- The company's EluPro product was recently approved and is central to its commercialization efforts, though profitability remains uncertain [sec_mda · as of 2025-08-14].
- Elutia faces ongoing litigation, including the FiberCel Litigation and VBM Litigation, which could impact financial resources [sec_mda · as of 2026-05-15].
- Revenue exhibits seasonality, with higher sales in Q4 due to hospital budget cycles and lower sales in Q1 as patient deductibles reset [sec_mda · as of 2026-08-14].
What works
- Elutia has successfully narrowed its focus to drug-eluting biomatrix solutions for breast reconstruction, a strategic shift that may improve operational efficiency [sec · filed 2025-09-09].
- The company has access to capital markets, having raised funds through registered offerings and private placements to support its operations [sec_mda · as of 2026-03-13].
- Elutia's EluPro product is newly approved, offering a potential growth driver in a specialized market [sec · filed 2025-02-03].
What to weigh
- Elutia has a history of net losses and negative cash flows, with a net loss of -$7.6M in the latest quarter and uncertainty about achieving profitability [sec] [sec_mda · as of 2025-08-14].
- The company faces significant litigation costs from the FiberCel and VBM lawsuits, which could strain financial resources [sec_mda · as of 2026-05-15].
- Cash burn and reliance on external financing create liquidity risk, as the company may need to raise additional capital through equity or debt [sec_mda · as of 2026-05-15].
- Commercial success of EluPro is unproven, and the company acknowledges risks in commercialization and market adoption [sec · filed 2025-02-03].
From the filings
Quoted directly from source documents.
Elutia's strategic shift to drug-eluting biomatrix solutions for breast reconstruction
“risks associated with shifting focus to our drug-eluting biomatrix solutions in the breast reconstruction area and away from our CIED Business”
SEC filings · September 9, 2025
Cash position as of March 31, 2026 was $28.5 million
“As of March 31, 2026, we had cash and cash equivalents of approximately $28.5 million.”
SEC MD&A · May 15, 2026
Elutia may never become profitable
“we are unable to predict when we will become profitable, and we may never become profitable.”
SEC MD&A · August 14, 2025
Ongoing FiberCel and VBM litigation
“the costs of defending against, or the damages payable in connection with the FiberCel Litigation and VBM Litigation”
SEC MD&A · May 15, 2026
Risks & what to watch (4)›
Key risks
- Profitability uncertainty — Elutia has a history of net losses and may never achieve profitability, which could impair its business [sec_mda · as of 2025-08-14].
- Litigation exposure — The FiberCel and VBM lawsuits could result in significant defense costs or damages, straining financial resources [sec_mda · as of 2026-05-15].
- Commercialization risk for EluPro — Successfully commercializing EluPro is uncertain and depends on market adoption, which may not materialize [sec · filed 2025-02-03].
- Liquidity and capital needs — Elutia may need to raise additional capital through equity or debt, which could dilute shareholders or increase debt [sec_mda · as of 2026-05-15].
What to watch
- Progress in commercializing EluPro and achieving revenue growth [sec · filed 2025-02-03].
- Outcomes of the FiberCel and VBM litigation, which could materially affect financials [sec_mda · as of 2026-05-15].
- Cash runway and any future capital raises, given the net loss and cash burn [sec] [sec_mda · as of 2026-05-15].
- Seasonal revenue patterns, particularly Q4 performance relative to Q1 [sec_mda · as of 2026-08-14].
Sources: SEC filings · SEC MD&A · Generated August 22, 2026 · How we verify sources →
Run ELUTIA INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ELUTIA INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
8.9 months
D/E 1.77 · 0% dilution
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 0.3%
- Days to cover
- 1.8
- Shares short
- 126,205
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ELUT short interestGovernance
Frequently asked questions
What is the AI investment thesis for ELUTIA INC.?
Elutia Inc. is a commercial-stage medical technology company focused on drug-eluting biomatrix solutions for breast reconstruction, having divested its Orthobiologics and CIED businesses to concentrate on its EluPro product line.
What is ELUTIA INC.'s lead drug candidate?
ELUTIA INC.'s most advanced tracked candidate is elupro (Approved) for Mitigate complications associated with the implantation of electronic medical devices such as pacemakers, internal defibrillators and neurostimulation devices.
Who is the CEO of ELUTIA INC.?
Dr. C. Randal Mills Ph.D. is the chief executive officer of ELUTIA INC. (ELUT).
Where is ELUTIA INC. headquartered?
ELUTIA INC. (ELUT) is headquartered in Gaithersburg, MD, United States.
What therapeutic areas does ELUTIA INC. focus on?
ELUTIA INC. develops therapies across Cardiovascular, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.